Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Lyophilized Drugs Focus of Delivery Device Suppliers

Lyophilized Drugs a Focus of Delivery Device Suppliers as Point-of-Use Reconstitution and Self-Administration Converge

Greystone Research Associates Finds High-Growth Markets Hinge on the Ability of Users to Safely and Reliably Reconsitute Solid Injectable Formulations

(Amherst, NH) – The ability of a growing number of New Chemical Entities (NCEs) to have commercial value as therapeutic drugs rests in the capability of developers to create formulations that render them stable at ambient temperatures. Once created, end users – caregivers and patients – must have a way to reconstitute them prior to administration. These requirements have fostered two industry segments designed to address the growing need for creating powder forms of injectables, and for developing devices that allow them to be reconstituted simply and without introducing medication errors.

Growth in the number of injectable drugs supplied in solid form for reconstitution prior to administration is being driven by the increase in drugs based on biologicals. These drugs are typically unstable at ambient temperatures and to preserve their shelf life must be either stored at low temperature (the so-call 'cold chain') or processed into a form that will preserve their pharmacological efficacy until they are ready for use. Because the cost of transporting and storing drugs using refrigeration is expensive and requires constant temperature monitoring to insure that the drug has not been exposed to environmental conditions that render it unsafe for use as a therapeutic product, technologies such as lyophilization are becoming more prevalent.

The packaging and technologies developed and marketed for safe and reliable reconstitution at the point of administration are benefiting from this market trend. Innovation and growth in drug reconstitution systems is being driven by two significant markets. The first is the self-administration of injectable biologicals. Several innovative injection devices package the drug powder and diluent in separate chambers within a single device. This allows the patient to reconstitute medication without the need for handling, measuring, and/or separate mixing steps, and enables biological drug developers to create lyophilized drug products indicated for chronic conditions that can be self-administered safety and reliably.

Another important trend is aimed at improving the safety of cytotoxic drug reconstitution. The focus here is on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers. Several companies are responding to this unmet need by commercializing systems for closed transfer of these drugs.

Detailed analysis of the devices and systems for reconstituting drugs at the point-of-care is included in a new and comprehensive report. The report – Point-of-Delivery Drug Reconstitution Systems - includes assessments of devices and therapeutic market segments, analysis of market factors, and profiles of market participants.

More information is available at
http://www.greystoneassociates.org

About Greystone

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.


Source: Greystone Research Associates

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Must Sell 20 Petrol Stations: Z Cleared To Buy Caltex Assets

Z Energy is allowed to buy the Caltex and Challenge! petrol station chains but must sell 19 of its retail sites and one truck-stop, the Commerce Commission has ruled in a split decision that acknowledges possible retail price coordination between fuel retailers occurs in some regions. More>>

ALSO:

Huntly: Genesis Extends Life Of Coal-Fuelled Power Station To 2022

Genesis Energy will keep its two coal and gas-fired units at Huntly Power Station operating until 2022, having previously said they'd be closed by 2018, after wringing a high price from other electricity generators who wanted to keep them as back-up. More>>

ALSO:

Dammed If You Do: Ruataniwha Irrigation Scheme Hits Farmer Uptake Targets

Enough Hawke's Bay farmers have signed up for water from the proposed Ruataniwha Water Storage Scheme for it to go ahead as long as a cornerstone institutional capital investor can be found to back it, its regional council promoter announced. More>>

ALSO:

Reserve Bank: OCR Stays At 2.25%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2.25 percent, in a decision traders had said could go either way, while predicting inflation will pick up as the slump in oil prices washes out of the data and capacity pressures start to build in the economy. More>>

ALSO:

Export Values Down: NZ Posts Biggest Annual Trade Deficit In 7 Years

New Zealand has recorded its biggest annual trade deficit since April 2009, reflecting weaker prices of agricultural commodities such as dairy products, beef and lamb, and increased imports of vehicles and machinery. More>>

ALSO:

Currency Events: NZ's New $5 Note Wins International Banknote Award

New Zealand’s new Brighter Money $5 note has been named Banknote of the Year in a prestigious international competition. The $5 note was awarded the IBNS Banknote of the Year title at the International Bank Note Society’s annual meeting. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news